BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/6/2018 3:22:41 AM | Browse: 1219 | Download: 2293
 |
Received |
|
2017-12-01 03:12 |
|
Peer-Review Started |
|
2017-12-01 14:02 |
|
First Decision by Editorial Office Director |
|
2017-12-12 23:42 |
|
Return for Revision |
|
2017-12-14 07:06 |
|
Revised |
|
2017-12-19 10:15 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2017-12-26 11:48 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2017-12-26 19:15 |
|
Articles in Press |
|
2017-12-26 19:15 |
|
Edit the Manuscript by Language Editor |
|
2018-01-02 08:12 |
|
Typeset the Manuscript |
|
2018-01-31 10:08 |
|
Publish the Manuscript Online |
|
2018-02-06 03:22 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Genetics & Heredity |
| Manuscript Type |
Basic Study |
| Article Title |
Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chun-Lan Xu, Yu Guo, Lei Qiao, Li Ma and Yi-Yi Cheng |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
31672435 |
| Graduate Starting Seed Fund of Northwestern Polytechnical University |
Z2017237 |
| National College Students Innovation, Experiment Program |
201610699266 |
|
| Corresponding Author |
Chun-Lan Xu, PhD, Associate Professor, The Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, 127 Youyixi Road, Xi’an 710072, Shaanxi Province, China. clxu@nwpu.edu.cn |
| Key Words |
Vasoactive intestinal peptide; Intestinal mucosal barrier; Tight junction; Toll-like receptors; Recombinant expression |
| Core Tip |
Vasoactive intestinal peptide (VIP) is a neuropeptide with potent anti-inflammatory activities. Recombinant VIP analogue (rVIPa with amino acid sequence “HSKAVFTKNYTRLRKQMAVKKYLNSILN”) with higher antimicrobial activity and stability than natural peptide was produced by an effective and low-cost production method. The current study first indicated that rVIPa could alleviated TNBS-induced colitis via TLR4/NF-κB-mediated signaling pathway. In summary, these results suggest a protective role and anti-inflammatory effect of rVIPa in inflammatory bowel disease and indicate that rVIPa has therapeutic potential for intestinal inflammatory disorders. The study contributes to identify and produce novel anti-inflammatory agents from human innate host defense mechanisms in the process of biological evolution. |
| Publish Date |
2018-02-06 03:22 |
| Citation |
Xu CL, Guo Y, Qiao L, Ma L, Cheng YY. Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats. World J Gastroenterol 2018; 24(6): 706-715 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i6/706.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i6.706 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
